par Bonnefoi, Herve;Piccart-Gebhart, Martine ;Bogaerts, Jan;Mauriac, Louis;Fumoleau, Pierre;Brain, Etienne;Petit, Thierry;Rouanet, Philippe;Jassem, Jacek;Blot, Emmanuel;Zaman, Khalil;Cufer, Tanja;Lortholary, Alain;Lidbrink, Elisabet;André, Sylvie;Litière, Saskia;Dal Lago, Lissandra ;Becette, Véronique;Cameron, David A;Bergh, Jonas;Iggo, Richard;EORTC 10994/BIG 1-00 Study Investigators,
Référence Lancet oncology, 12, 6, page (527-539)
Publication Publié, 2011-06
Référence Lancet oncology, 12, 6, page (527-539)
Publication Publié, 2011-06
Article révisé par les pairs
Titre: |
|
Auteur: | Bonnefoi, Herve; Piccart-Gebhart, Martine; Bogaerts, Jan; Mauriac, Louis; Fumoleau, Pierre; Brain, Etienne; Petit, Thierry; Rouanet, Philippe; Jassem, Jacek; Blot, Emmanuel; Zaman, Khalil; Cufer, Tanja; Lortholary, Alain; Lidbrink, Elisabet; André, Sylvie; Litière, Saskia; Dal Lago, Lissandra; Becette, Véronique; Cameron, David A; Bergh, Jonas; Iggo, Richard; EORTC 10994/BIG 1-00 Study Investigators, |
Informations sur la publication: | Lancet oncology, 12, 6, page (527-539) |
Statut de publication: | Publié, 2011-06 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Adult |
Aged | |
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
Breast Neoplasms -- chemistry -- drug therapy -- mortality | |
Female | |
Humans | |
Middle Aged | |
Mutation | |
Neoadjuvant Therapy | |
Receptor, erbB-2 -- analysis | |
Receptors, Estrogen -- analysis | |
Taxoids -- administration & dosage -- therapeutic use | |
Tumor Suppressor Protein p53 -- genetics -- physiology | |
Note générale: | Clinical Trial, Phase III |
Journal Article | |
Randomized Controlled Trial | |
Research Support, N.I.H., Extramural | |
Research Support, Non-U.S. Gov't | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:1470-2045 |
info:doi/10.1016/S1470-2045(11)70094-8 | |
info:pii/S1470-2045(11)70094-8 | |
info:scp/79957527931 | |
info:pmid/21570352 |